Flu vaccine sales should only get better as avian flu types continue to mutate. Slow and steady. Moving forward on pipeline drugs. It might not be too exciting but SVA is beginning the conversion from biotech to Chinese Big Pharma. One day soon consistent sales and earnings and a dividend.
All your commentary is appreciated, donormaster. I've been in and out of this stock, waiting for some indication that they plan on being the preeminent Chinese vaccine producer. If the science is good then there's no reason SVA can't compete favorably with traditional pharma for business. I'd like to see some decent earnings so investors won't look at this as some fly by night Asian biotech.
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and full year, ended December 31, 2014, before market opens on Monday, April 20, 2015. The Company will host a conference call on Monday, April 20, 2015, at 8:00 a.m. EDT (Monday, April 20, 2015 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
Reread that SA article and I'm beginning to think that the Pfizer departure should be very favorable long term for SVA. Seller done at $4.93-4.99. Need to get over the $5.10-5.15 level then on to $5.35. Best of luck out there to all longs.
I keep thinking that China will make a concerted effort to wean itself away from non Asian vaccine sources and anoint SVA as it's primary provider but it hasn't happened. Hoping for favorable surprises on earnings and news releases some time next week.
IDK. I guess we'll have to look at the 13F's on May 15 to determine if my hunch is correct. A seller is a seller. Thought it had the earmark of Renaissance Tech. Guess it doesn't make a difference who is selling. When it's all done then maybe we move onwards and upwards. SVA has been a disappointment but that can change in the time it takes to release favorable earnings and a positive outlook.
But at lower price. $4.93.
Reread the PFE article and thought it wasn't as bullish for SVA as I originally did. Bummer. Still looking for some indication that the CFDA is looking for self preparedness in case of pandemic. Earnings and some PR due soon, I guess. If not then it's gonna be a long spring.
Could this mean that China is finally going to be providing it's own vaccines rather than depend on foreign sources? I certainly hope so. It's about time for Chinese "science" to be considered more than crushed Rhinoceros horn. So many talented Chinese biologists in the US. My wife works with them at Columbia U.. It's about time for Chinese to harvest their own to provide for their own people so they won't come up short if God forbid there ever is a serious pandemic.
To me, it looks like Renaissance Tech selling out. They have been known to eliminate a position in a big way when the numbers dictate. It hasn't taken the stock down but the sell down is the most likely reason SVA didn't participate in the biotech bubble. The price has recently been capped at $5.05. Hopefully as soon as this is cleaned up, with some favorable earnings, punctuated by some good news on pipeline drugs SVA can reach new 52 week highs.
Seeking Alpha has earnings being released "before the open" Monday. It was on the CNBC site under Seeking Alpha's "Next Week in Biotech." Guess we'll find out the easy or hard way if earnings are out today within the hour.
Eli Lilly & Co. agreed to form one of the broadest collaborations to date between a large Western drug maker and a Chinese biotechnology company, Innovent Biologics?
And when is SVA actually releasing earnings? This afternoon? Thanks.
Fingers and toes crossed for great earnings and favorable news releases. With this company and their lack of information disclosure, crossing digits is my investment strategy. I still believe that Asian science is as good if not better than Western, until it isn't. Best of luck. to all longs.
Hope you're right. I've got a 5,000 share bet that the Chinese DO give a darn about having their own vaccination provider instead of relying on other non Asian sources. BUT given the lack of information released by SVA on vaccine progress it seems like SVA isn't remotely trying. There isn't any company news for anything. What is that?
Unfortunately for us SVA holders Chinese leaders view a pandemic as population control. Therefore there isn't any announcement of more funds being being directed to creating a vaccine. When the pandemic comes they'll just buy vaccines from non Chinese pharma's Sanofi, PFE, GSK and MRK, if there is any left after those companies vaccinate their own populations.